Feeling sick?

Use the Symptom Checker to check your symptoms

Add this to your profile
Banner for leaf pages 2

Omalizumab (Xolair)

Also known as Xolair

Omalizumab (trade name Xolair, Roche/Genentech and Novartis) is a humanized antibody used to reduce sensitivity to inhaled allergens, especially in the control of moderate to severe allergic asthma which does not react to high doses of corticosteroids. It is approved for use in countries across the world, although some countries restrict its use to patients over 12 years old. Omalizumab's cost is high, ranging from $6,000 to $24,000 a year (USD), limiting availability in developing countries and leading to rationing in countries with universal healthcare such as the UK.

Source: Wikipedia

Estimated Total Cost: $2065.93 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed omalizumab to treat asthma, seasonal allergies (hay fever), rabies, and pick disease.

Ajax-loader Loading...